Avalo Therapeutics
AVTX
43 hedge funds and large institutions have $10.9M invested in Avalo Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 18 reducing their positions, and 27 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
34% less funds holding
Funds holding: 65 → 43 (-22)
78% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 27
78% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 18
81% less capital invested
Capital invested by funds: $56.2M → $10.9M (-$45.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$470K |
| 2 |
E
Ergoteles
New York
|
+$132K |
| 3 |
Goldman Sachs
New York
|
+$58.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$28.1K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$20.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.17M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$869K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$554K |
| 4 |
IHAM
Integral Health Asset Management
New York
|
-$507K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$467K |
AVTX Hedge Fund Activity: Q2 2022 in Review
43 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2022, worth a combined $10.9M — down 81% from $56.2M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of AVTX and 6 opened new positions — a net loss of 21 holders — while 18 trimmed existing stakes and 4 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $470K. The largest seller was BlackRock, cutting an estimated $1.17M.
- 43 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2022, down from 65 in Q1 2022.
- Funds reported $10.9M of Avalo Therapeutics stock for Q2 2022, down 81% quarter-over-quarter.
- 6 funds opened new Avalo Therapeutics positions in Q2 2022 and 27 closed out, a net change of -21 holders.
- The largest Avalo Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $470K added.
- The largest Avalo Therapeutics seller in Q2 2022 was BlackRock, an estimated $1.17M sold.
Based on aggregated 13F filings for Q2 2022.